Skip to main content
Premium Trial:

Request an Annual Quote

Cellectis Nabs €40M Credit Facility From European Investment Bank to Aid Cell Therapy Development

NEW YORK – Cellectis said Thursday that it has entered a €40 million ($42.6 million) credit facility agreement with the European Investment Bank.

The Paris-based gene editing company plans to use the funds to support the development of a pipeline of allogeneic CAR T-cell product candidates: UCART22, UCART20x22, UCART123, and UCARTCS1.

The credit facility is divided into three tranches of €20 million, €15 million, and €5 million, respectively, and disbursement of each portion is subject to certain conditions, which Cellectis said have yet to be satisfied.

These conditions include the completion of certain clinical development milestones by Cellectis' licensee, collection of payments associated with existing or new partnerships, and the instigation of clinical trials.

According to Cellectis, the three tranches will be available within 36 months following the signing of a finance contract, and the credit will carry a decreasing fixed payment-in-kind interest rate per tranche — 8 percent for Tranche A, 7 percent for Tranche B, and 6 percent for Tranche C — with a maturity of six years for each tranche.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.